PIK3ACA mutations are associated with a worse response to first-line chemotherapy (11) and a phase I clinical trial has shown evidence for the sensitivity of PIK3CA mutated colorectal cancer to the PIK3a-selective inhibitor (44). Here, PIK3CA is linked to colorectal cancer.